Information  X 
Enter a valid email address

Iofina PLC (IOF)

  Print      Mail a friend       Annual reports

Wednesday 13 June, 2018

Iofina PLC

Result of AGM

RNS Number : 2802R
Iofina PLC
13 June 2018
 

 

13 June 2018

Iofina plc

("Iofina", the "Group", or the "Company")

(LSE AIM: IOF)

 

Result of AGM

 

Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, is pleased to announce that at its Annual General Meeting ("AGM") held earlier today, Wednesday 13 June 2018, all resolutions were duly passed.

The Company's Annual Report and Accounts, together with the notice of AGM, were posted to shareholders on 30 April 2018 and are available to view on the Company's investor site at www.iofina.com.

Enquiries:

 

Iofina plc

Dr. Tom Becker, CEO & President

Tel: +44 (0)20 3006 3135

 

finnCap Ltd

Christopher Raggett/Giles Rolls/Camille Gochez

Tel: +44 (0)20 7220 0500

 

Media Contact:

Yellow Jersey

Charles Goodwin/Harriet Jackson

Tel: +44 (0)7544 275 882

 About Iofina:

Iofina specialises in the exploration and production of iodine, halogen based specialty chemical derivatives and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America, based on Iofina's WET® IOsorb® technology. Iofina has production operations in the United States, specifically in Kentucky and Oklahoma. It is a vertically integrated company, covering the process from the production of iodine in the field, to the manufacture of the chemical end-products derived from iodine, supplying them to the consumer, and the recycling of iodine using iodinated side-streams from waste chemical processes. Iofina utilises its portfolio of patented and patent-pending technology, and proprietary methods and trademarks throughout all business lines.

www.iofina.com

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGSFLFSDFASEFM

a d v e r t i s e m e n t